Navigation Links
Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Date:2/26/2009

rax. The Company expects to receive at least $150 million from this sale in 2009, with most of the revenue expected in the first quarter. ABthrax is being developed under a contract entered into in 2006 with the Biomedical Advanced Research and Development Authority (BARDA) of the Office of the Assistant Secretary for Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS). Also under the contract, the Company plans to file a Biologics License Application (BLA) with the FDA in the second quarter of 2009. HGS will receive an additional $15 million from the U.S. Government upon FDA licensure of ABthrax.

Albuferon(R): Positive Data Announced for First of Two Phase 3 Trials in Chronic Hepatitis C Patients; Results of Second Phase 3 Trial Expected in March 2009

In December 2008, HGS reported that Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in ACHIEVE 2/3, the Phase 3 clinical trial of Albuferon in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C. The data showed that the rate of sustained virologic response was comparable for the 900-mcg dose of Albuferon administered every two weeks, vs. the standard 180-mcg dose of peginterferon alfa-2a administered once weekly. Rates of serious adverse events, severe adverse events and discontinuations due to adverse events were also comparable. ACHIEVE 1, the second Albuferon Phase 3 clinical trial, is being conducted in treatment-naive patients with genotype 1 chronic hepatitis C; data are expected in March 2009. Assuming success in Phase 3, HGS expects that global marketing applications will be filed in fall 2009. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

LymphoStat-B(R): Phase 3 Results Expected in July and November 2009


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
2. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
3. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
4. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
5. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
6. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
7. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
8. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
9. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
10. 2008 Human Research Protection Award Recipients Announced
11. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  Today DePuy Synthes Companies of Johnson ... systems featuring its proprietary variable angle locking technology. ... to match patient anatomy and fracture pattern and ... systems are being introduced in conjunction with the ... the International Federation of Foot & Ankle Societies ...
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- ... Oxybutynin Hydrochloride Industry, 2009-2019 is a professional ... Chinese Oxybutynin Hydrochloride industry. The report firstly ... including its classification, application and manufacturing technology. ... top manufacturers of Oxybutynin Hydrochloride listing their ...
(Date:9/19/2014)... 19, 2014 Research ... the addition of the "Global Gynecological ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... classified into wide categories based on their ... treatment of different gynecological conditions that affect ...
Breaking Medicine Technology:DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3
(Date:9/19/2014)... (PRWEB) September 20, 2014 Nearly 780 ... of Common Pleas where a meeting took place to ... complaints pending in the court’s mass tort program. ... meet this past week at the Complex Litigation Center ... consolidated for pretrial proceedings. The Risperdal lawsuits filed against ...
(Date:9/19/2014)... (Washington, DC) (PRWEB) September 19, 2014 ... to inflate sales of brand drugs among patients with ... D, according to a new report from ... the Inspector General (OIG). Federal anti-kickback laws prohibit suppliers ... are subsidized by the federal government. , The report ...
(Date:9/19/2014)... Unbound , an international humanitarian organization based ... the Philippines being affected by both a tropical storm and ... to the nearest public schools while others moved to higher ... winds to portions of the northern Philippines. , The ... with more than 10 feet of water. , “It ...
(Date:9/19/2014)... As kids transition from elementary to middle school, they ... recent study. But the researchers studying U.S ... and physical bullying declines as students get older. ... must address all types of bullying as well as ... said. The study was published recently in School ...
(Date:9/19/2014)... More than half of human cancers have ... yet how these signals are controlled during tumor ... PhD, MD, and Svetlana Fayngerts, PhD, both researchers ... at the Perelman School of Medicine, University of ... described oncogenic protein, promotes cancer by targeting these ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:New cancer drug target involving lipid chemical messengers 2
... Washington, D.C., and Meet With Elected,Officials, WASHINGTON, March ... Washington, D.C., this April 1 to meet with,congressional leaders ... Disabilities Act, support for epilepsy public health,programs and more ... is one of 50 young people with epilepsy participating ...
... DENVER, March 14 Birner Dental Management,Services, Inc. ... dental practices,announced its regular quarterly dividend. The Company,s ... of 17 cents per share of common,stock. The ... of record,March 28, 2008., Birner Dental Management ...
... ( http://www.nhs.uk ), the,digital ,front door, to ... package on,pregnancy, aimed at helping people find ... Based on NHS accredited information, the pregnancy ... staying healthy and fit during pregnancy,including eating ...
... STE ) today announced that its Board ... $300 million in shares of STERIS common stock. ... of,February 29, 2008. This share repurchase authorization replaces ... Through March,13, 2008, the Company has repurchased approximately ...
... plant that processed vermiculite tainted with asbestos-like fibers that originated ... scarring and thickening of the membrane that lines the chest ... materialeven those who were exposed at or below current legal ... 20 times its original size when rapidly heated and has ...
... its Selection ... of All-Natural Cookies, SAN DIEGO, March ... of "Nana,s Fiber Cookie Bars." The,new high-fiber cookie bars provide an ... Fiber Bar will complement the company,s,existing lines of healthy and delicious ...
Cached Medicine News:Health News:Tennessee Youth Named National Epilepsy Spokesperson 2Health News:STERIS Corporation Announces New $300 Million Share Repurchase Authorization 2Health News:STERIS Corporation Announces New $300 Million Share Repurchase Authorization 3Health News:Legal exposure to asbestos-like material linked to lung damage 25 years later 2Health News:Legal exposure to asbestos-like material linked to lung damage 25 years later 3Health News:Have Your Cookie and Fiber too With Nana's Newest Cookie Bar 2
Solid steel construction for lifelong quality. Strong, smooth and quiet electro-mechanical up/down movement. Dual castor, locking wheels for use on carpet or tile flooring. Easy cleaning, deluxe lami...
Trial lens set +/- Cyl....
... control panel with 3 charging wells. Available ... Colonial Blue and Cinnamon. Spring balanced refractor ... and steel construction for lifelong quality. Sealed ... up/down chair movement. Chair back reclines manually ...
Our Ophthalmic Diagnostic Sets offer everything an eye care specialist needs. Complete your set with your choice of ophthalmoscope, retinoscope, handle, and case....
Medicine Products: